Protecting Health Care and Lowering Costs Act
Summary
The Protecting Health Care and Lowering Costs Act permanently extends enhanced premium tax credits, directly expanding the customer base and revenue for health insurance providers. The bill also repeals specific Medicaid, Medicare, and health-related tax provisions from the One Big Beautiful Bill Act, which is a net positive for the healthcare industry.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The bill permanently extends enhanced premium tax credits, expanding the health insurance market.
- 2.Repeals of prior health-related tax provisions are a net positive for the healthcare industry.
- 3.Health insurance providers and PBMs will see increased revenue and customer base.
Market Implications
This legislation creates a bullish environment for the healthcare sector, specifically for health insurance providers and pharmacy benefit managers. Companies like UnitedHealth Group ($UNH), Elevance Health ($ELV), Cigna ($CI), Humana ($HUM), and CVS Health ($CVS) will directly benefit from an expanded customer base and increased premium revenue. Investors should anticipate positive earnings revisions and sustained growth for these entities as the market for insured individuals grows permanently.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
No Surprises Act Enforcement Act
Living Donor Protection Act of 2025
Lowering Drug Costs for American Families Act
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Access to Breast Cancer Diagnosis Act of 2025
Improving Seniors’ Timely Access to Care Act of 2025
Increasing Access to Lung Cancer Screening Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.